FindTrial
Sign In

A clinical trial to study the efficiency of two drugs terlipressin and noradrenaline in patients with low blood pressure and liver failure.

Comparison of terlipressin infusion versus noradrenaline in septic shock in patients with acute on chronic liver failure.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036920
Enrollment
60
Registered
2021-09-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: Terlipressin infusion: Starting at dose of 2.6 microgram/kg/min , MAP shall be assessed every 30 minutes, if MAP less than 65mmHg , infusion rate gradually increased till maximum dose

Sponsors

Pt BD Sharma Pgims rohtak
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients between age 18 to 70 years. 2. Patients of Acute-on-chronic liver failure with sepsis in septic shock. 3. Patients who gives informed consent and in case patient is not in fully coherent state,consent given by first degree relative shall be taken.

Exclusion criteria

Exclusion criteria: 1. Patients with any chronic respiratory disease, chronic kidney disease. 2. History of DM , hypertension. 3. History of valvular heart disease, coronary artery disease. 4. Hepatocellular carcinoma 5. Pregnant females 6. History of cerebrovascular disease

Design outcomes

Primary

MeasureTime frame
Response of shock to therapy.Timepoint: Mean arterial blood pressure I.e. MAP assessed every 30 minutes—

Secondary

MeasureTime frame
1 Mortality at 3,7,14 and 28 day 2. Duration of hospital stay. 3 Cumulative dose of drug. 4 other events - a) upper gastrointestinal bleed b) acute kidney injury c) hepatic encephalopathyTimepoint: Mortality at 3, 7, 14 and 28 day—

Countries

India

Contacts

Public ContactDr anjali

Pt.B.D. Sharma pgims rohtak

taranagupta@gmail.com9914048899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026